|
J. Biol. Chem., Vol. 278, Issue 18, 15484-15494, May 2, 2003
Biochemical Characterization of Proline Racemases from the Human
Protozoan Parasite Trypanosoma cruzi and Definition of
Putative Protein Signatures*
Nathalie
Chamond §,
Christophe
Grégoire §¶,
Nicolas
Coatnoan ,
Catherine
Rougeot ,
Lucio Holanda
Freitas-Junior ,
José Franco
da Silveira**,
Wim M.
Degrave , and
Paola
Minoprio §§
From the Departments of Immunology and
Parasitology, Institut Pasteur, Paris, 75724, France,
** Department of Microbiology, Immunology and Parasitology,
Unifesp/Escola Paulista de Medicina, Sao Paulo
04023-062, Brazil, and  Department of
Biochemistry and Molecular Biology, Instituto Oswaldo Cruz, Rio
de Janeiro 21045-900, Brazil
Proline racemase catalyzes the
interconversion of L- and
D-proline enantiomers and has to date been described in
only two species. Originally found in the bacterium Clostridium
sticklandii, it contains cysteine residues in the active site and
does not require co-factors or other known coenzymes. We recently
described the first eukaryotic amino acid (proline) racemase, after
isolation and cloning of a gene from the pathogenic human parasite
Trypanosoma cruzi. Although this enzyme is intracellularly
located in replicative non-infective forms of T. cruzi,
membrane-bound and secreted forms of the enzyme are present upon
differentiation of the parasite into non-dividing infective forms. The
secreted form of proline racemase is a potent host B-cell mitogen
supporting parasite evasion of specific immune responses. Here we
describe that the TcPRAC genes in T. cruzi encode functional intracellular or secreted versions of
the enzyme exhibiting distinct kinetic properties that may be relevant
for their relative catalytic efficiency. Although the
Km of the enzyme isoforms were of a similar order
of magnitude (29-75 mM), Vmax
varied between 2 × 10 4 and 5.3 × 10 5 mol of L-proline/s/0.125 µM
of homodimeric recombinant protein. Studies with the enzyme-specific
inhibitor and abrogation of enzymatic activity by site-directed
mutagenesis of the active site Cys330 residue reinforced
the potential of proline racemase as a critical target for drug
development against Chagas' disease. Finally, we propose a protein
signature for proline racemases and suggest that the enzyme is present
in several other pathogenic and non-pathogenic bacterial genomes of
medical and agricultural interest, yet absent in mammalian host,
suggesting that inhibition of proline racemases may have therapeutic potential.
*
This work was supported in part by Institut Pasteur and CNRS
URA 1960.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AY 1409447.
§
Contributed equally to this work.
¶
Fellow of the Pasteur Institute.
§§
To whom correspondence should be addressed. Tel./Fax:
33-1-45-68-86-15; E-mail: pmm@pasteur.fr.
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. M. Spera, J. E. Ugalde, J. Mucci, D. J. Comerci, and R. A. Ugalde
A B lymphocyte mitogen is a Brucella abortus virulence factor required for persistent infection
PNAS,
October 31, 2006;
103(44):
16514 - 16519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Buschiazzo, M. Goytia, F. Schaeffer, W. Degrave, W. Shepard, C. Grégoire, N. Chamond, A. Cosson, A. Berneman, N. Coatnoan, et al.
Crystal structure, catalytic mechanism, and mitogenic properties of Trypanosoma cruzi proline racemase
PNAS,
February 7, 2006;
103(6):
1705 - 1710.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|